Clinical Trials
Open
Phase
Accrual
0%
SWOG Clinical Trial Number
21CTP.HN01
Phase II Study of Amivantamab carboPlatin and pacliTaxel in recurrent metastatic Head and Neck cancer (CAPT-HN) Study Synopsis
Status Notes
Activation - Effective 09/15/2025
SWOG Clinical Trials Partinerships
https://www.swogctp.org/trials/21ctphn01/
SWOG Clinical Trials Partinerships
https://www.swogctp.org/trials/21ctphn01/
Research Committee(s)
SWOG CTP
Head and Neck Cancer
Activated
09-15-2025
ClinicalTrials.gov Registry Number
07062354
Open
Phase
Accrual
1%
SWOG Clinical Trial Number
S2427
Single Arm Phase II Study of Bladder Preservation with Immunoradiotherapy after a Clinically Meaningful Response to Neoadjuvant Therapy in Patients with Muscle Invasive Bladder Cancer (BRIGHT)
Status Notes
Active as of 9/4/2025.
Research Committee(s)
Genitourinary Cancer
Activated
09-04-2025
ClinicalTrials.gov Registry Number
07061964
Open
Phase
Accrual
2%
SWOG Clinical Trial Number
S2417CD
A Pragmatic Randomized Controlled Trial to Evaluate the Effectiveness of an Intervention called Current Together After Cancer (CTAC) to Promote Guideline-Concordant Colorectal Cancer Surveillance
Status Notes
This study is open to accrual, effective 8/4/2025 at 12:00 p.m. PT.
Research Committee(s)
Cancer Care Delivery
Gastrointestinal Cancer
Activated
08-04-2025
ClinicalTrials.gov Registry Number
NCT 07018869
Open
Phase
Accrual
10%
SWOG Clinical Trial Number
S1800E
A Randomized Phase II/III Study of Docetaxel and Ramucirumab with or without Cemiplimab for Participants Previously Treated with Immunotherapy for Stage IV or Recurrent Non-Small Cell Lung Cancer (Lung-MAP Non-Matched Sub-Study)
Status Notes
Effective April 28, 2025 at 12:00 p.m. Pacific Time, sub-study S1800E will be open to accrual. This is a potential FDA Registration Trial. Additional site requirements include:
• maintenance of a Trial Master File (See the Trial Master File guidance document, accessible from the Protocol Workbench at https://www.swog.org/clinical-trials/protocol-workbench)
• completion of a protocol specific Delegation of Task Log (DTL) (see Section 13.2)
• additional monitoring (see Section 18.3)
• maintenance of a Trial Master File (See the Trial Master File guidance document, accessible from the Protocol Workbench at https://www.swog.org/clinical-trials/protocol-workbench)
• completion of a protocol specific Delegation of Task Log (DTL) (see Section 13.2)
• additional monitoring (see Section 18.3)
Research Committee(s)
LungMAP
Activated
04-28-2025
ClinicalTrials.gov Registry Number
NCT06616584
Open
Phase
Accrual
8%
SWOG Clinical Trial Number
MM1OA-S03
A Randomized Phase 2 Trial of ASTX727 and Venetoclax Compared with ASTX727, Venetoclax, and Enasidenib for Newly Diagnosed Older Adults with IDH2 Mutant AML: A myeloMATCH Substudy
Research Committee(s)
myeloMATCH
Leukemia
Activated
04-01-2025
ClinicalTrials.gov Registry Number
NCT06672146
Open
Phase
Accrual
2%
SWOG Clinical Trial Number
S2414
INcorporating pathologic reSponse in patIents with early staGe lung cancer to optimize immunotHerapy in the adjuvanT setting (INSIGHT)
Status Notes
Initial Activation-Effective March 14, 2025, at 12:00 p.m. Pacific Time
Research Committee(s)
Lung Cancer
Symptom Control and Quality of Life
Activated
03-14-2025
ClinicalTrials.gov Registry Number
06498635